Welcome to Trino Therapeutics
Ireland’s Trino Therapeutics is a privately held biotech company focused on developing oral small molecules for the treatment and unmet management of inflammatory bowel disease (IBD) and other inflammatory indications. Trino was initially spun out of Trinity College Dublin with seed investment, support from Enterprise Ireland and translational funding from Wellcome Trust Innovations. In 2013, the company closed a €9m Series ‘A’ financing led by Fountain Healthcare Partners (Dublin, Ireland) and Wellcome Trust (UK) to advance its lead candidate through preclinical development and into early clinical trials. Its first orally active candidate, PH46A, is currently under evaluation in Phase I clinical trials.